Antibodies directed against ICOS and uses thereof
US-9676852-B2 · Jun 13, 2017 · US
Antibodies directed against ICOS and uses thereof
US9975950B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9975950-B2 |
| Application number | US-201715492520-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 20, 2017 |
| Priority date | Mar 31, 2011 |
| Publication date | May 22, 2018 |
| Grant date | May 22, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treatment of cancer in a patient in need thereof, the method comprising administering to the patient an antibody directed against human Inducible T-cell costimulator (ICOS), wherein said cancer is determined to have regulatory T cells (Treg cells) present in a tumor microenvironment and wherein said antibody reduces the number and/or activity of the Treg cells in the tumor microenvironment, and wherein said cancer is selected from the group consisting of ovarian cancer, cervical cancer, breast cancer, colon cancer, lung cancer, prostate cancer, head and neck cancer, pancreatic cancer, bladder cancer, colorectal cancer, kidney cancer, stomach cancer, skin cancer, and esophageal cancer. 2. The method of claim 1 , wherein said antibody reduces the number of Treg cells in a tumor microenvironment. 3. The method of claim 1 , wherein said antibody reduces the activity of Treg cells in a tumor microenvironment. 4. The method of claim 1 , wherein said cancer is ovarian cancer. 5. The method of claim 1 , wherein said cancer is cervical cancer. 6. The method of claim 1 , wherein said cancer is breast cancer. 7. The method of claim 1 , wherein said cancer is colon cancer. 8. The method of claim 1 , wherein said cancer is lung cancer. 9. The method of claim 1 , wherein said cancer is prostate cancer. 10. The method of claim 1 , wherein said cancer is head and neck cancer. 11. The method of claim 1 , wherein said cancer is pancreatic cancer. 12. The method of claim 1 , wherein said cancer is bladder cancer. 13. The method of claim 1 , wherein said cancer is colorectal cancer. 14. The method of claim 1 , wherein said cancer is kidney cancer. 15. The method of claim 1 , wherein said cancer is stomach cancer. 16. The method of claim 1 , wherein said cancer is skin cancer. 17. The method of claim 1 , wherein said cancer is esophageal cancer.
Assignees
Inventors
Classifications
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for immunological or allergic disorders · CPC title
Immunomodulators · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Antibacterial agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9975950B2 cover?
- The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induc…
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med, Inst Jean Paoli & Irene Calmettes, Univ Aix Marseille, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2818. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).